Re-Listing Still The Best Option For Chinese Life Sciences Firms?
This article was originally published in PharmAsia News
Executive Summary
There has been a trend for US-listed Chinese life sciences and health care companies to go private and eventually relist back home. But this process is not only becoming increasingly cumbersome, there is a lot more to worry about than just getting a higher valuation, insiders tell PharmAsia News.
You may also be interested in...
Asia-Pacific Healthcare Investment Solid Despite Global Worries
Solid fundamentals in the Asia-Pacific healthcare market are continuing to attract significant investment and M&A activity with no signs of a slowdown, despite fears over China’s economic growth and negative factors in the wider global economy. Medtech, digital health and health services are all set to benefit, experts say.
Strong Innovent IPO Restoring Faith In HK Biotech Listings?
Suzhou-based Innovent Bio becomes the fourth biotech from mainland China to go public in Hong Kong, and its strong first-day performance may have given the seemingly spooked market so far for such companies a shot of confidence.
China Biotech Innovation Reaching Tipping Point?
A rapidly reforming policy and regulatory environment and a growing culture of innovation are encouraging capital and talent to pour into China, making it a question of when, rather than if, the payoffs will come for both consumers and investors.